Bridgebio Pharma, INC Form 4 insider transactions

Thomas Trimarchi, CFO of BridgeBio Pharma, disposed of 21,317 shares of common stock to satisfy tax obligations related to vesting restricted stock units.

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, reports the withholding of shares to cover tax obligations related to vested restricted stock units.

KKR Genetic Disorder L.P. sold 6 million shares of BridgeBio Pharma at $34.20 per share.

Director Francis McCormick reported gifting shares of BridgeBio Pharma stock, both directly and indirectly through a trust.

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., sold 1,026 shares of common stock at a price of $38.5079 on May 2, 2025.

Director Andrew Lo sold 100,000 shares of BridgeBio Pharma (BBIO) on May 2, 2025, at an average price of $38.499 per share.

BridgeBio Pharma's CEO, Neil Kumar, sold 75,000 shares of common stock at an average price of $34.107 per share on April 22, 2025, according to a Form 4 filing.

Director Andrea Ellis exercised stock options and sold shares of BridgeBio Pharma, Inc. under a pre-arranged 10b5-1 trading plan.

Director Andrea Ellis exercised stock options and sold shares of BridgeBio Pharma, Inc. under a pre-arranged 10b5-1 trading plan.

Neil Kumar, CEO of BridgeBio Pharma, sold 75,000 shares of common stock at an average price of $36.8659 on March 25, 2025, according to a Form 4 filing.

BridgeBio Pharma's CFO, Thomas Trimarchi, received a grant of restricted stock units and also executed a limited power of attorney for SEC filings.

Neil Kumar, CEO of BridgeBio Pharma, reports the acquisition of stock options and restricted stock units, according to a Form 4 filing with the SEC.

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, reports the acquisition of restricted stock units.

Director Hannah Valantine exercised stock options and sold shares of BridgeBio Pharma, Inc. on March 6, 2025, according to a Form 4 filing.

KKR Genetic Disorder L.P. sold 6 million shares of BridgeBio Pharma at $32.96 per share.

Brian Stephenson, CFO of BridgeBio Pharma, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Neil Kumar, CEO of BridgeBio Pharma, sold shares of common stock on February 25, 2025, under a pre-arranged Rule 10b5-1 sales plan.

Thomas Trimarchi, President and COO of BridgeBio Pharma, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Brian Stephenson, CFO of BridgeBio Pharma, reports the acquisition and disposal of common stock and restricted stock units.

Neil Kumar, CEO of BridgeBio Pharma, reports the acquisition and disposal of common stock and restricted stock units, including transactions to cover tax obligations and sales under a pre-arranged Rule 10b5-1 plan.

Viking Global Investors LP sold 3,065,616 shares of BridgeBio Pharma, Inc. at a price of $34.9 per share on January 31, 2025.

BridgeBio Pharma's CFO, Brian C. Stephenson, exercised stock options and sold shares on January 28, 2025, according to a recent SEC filing.

BridgeBio Pharma's CEO, Neil Kumar, sold a total of 599,999 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

A BridgeBio Pharma director, Frank McCormick, amended a previous filing to correct the reported number of shares held, reflecting a gift of 7,400 shares.

Director Ali J. Satvat exercised stock options to acquire BridgeBio Pharma shares at various prices on December 30, 2024.

Director Frank McCormick disposed of 7,400 shares of BridgeBio Pharma stock on December 26, 2024, reducing his direct holdings.

BridgeBio Pharma CEO Neil Kumar reported a transfer of shares, both directly and indirectly, on December 24, 2024.

BridgeBio Pharma's CEO, Neil Kumar, was granted 121,951 restricted stock units (RSUs) that vest over two years.

BridgeBio Pharma's CFO, Brian C. Stephenson, received 42,683 restricted stock units (RSUs) that vest over two years.

BridgeBio Pharma's President and COO, Thomas C. Trimarchi, received a grant of 50,000 restricted stock units (RSUs) under the company's 2021 incentive plan.